Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) EV-to-Revenue : (As of Jun. 15, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Lixte Biotechnology Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Lixte Biotechnology Holdings's enterprise value is $0.00 Mil. Lixte Biotechnology Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Lixte Biotechnology Holdings's EV-to-Revenue for today is .

The historical rank and industry rank for Lixte Biotechnology Holdings's EV-to-Revenue or its related term are showing as below:

During the past 13 years, the highest EV-to-Revenue of Lixte Biotechnology Holdings was 337.34. The lowest was 21.57. And the median was 62.03.

LIXTW's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.145
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-15), Lixte Biotechnology Holdings's stock price is $0.0824. Lixte Biotechnology Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Lixte Biotechnology Holdings's PS Ratio for today is .

Lixte Biotechnology Holdings EV-to-Revenue Historical Data

The historical data trend for Lixte Biotechnology Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings EV-to-Revenue Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

Lixte Biotechnology Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Lixte Biotechnology Holdings's EV-to-Revenue

For the Biotechnology subindustry, Lixte Biotechnology Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lixte Biotechnology Holdings's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's EV-to-Revenue falls into.

Lixte Biotechnology Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Lixte Biotechnology Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	0.000	/	0
	=

Lixte Biotechnology Holdings's current Enterprise Value is $0.00 Mil.
Lixte Biotechnology Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Lixte Biotechnology Holdings (NAS:LIXTW) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Lixte Biotechnology Holdings's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.0824	/
	=

Lixte Biotechnology Holdings's share price for today is $0.0824.
Lixte Biotechnology Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Lixte Biotechnology Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXTW) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.